Bioventus
BVS
98 hedge funds and large institutions have $452M invested in Bioventus in 2021 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 41 increasing their positions, 9 reducing their positions, and 14 closing their positions.
356% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 9
207% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 14
134% more capital inflows, than outflows
Capital inflows: $158M | Capital outflows: $67.4M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
42% more funds holding
Funds holding: 69 → 98 (+29)
8.07% less ownership
Funds ownership: 60.51% → 52.45% (-8.1%)
90% less call options, than puts
Call options by funds: $94K | Put options by funds: $958K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JIC
Juniper Investment Company
New York
|
+$30.5M |
| 2 |
Royce & Associates
New York
|
+$25.4M |
| 3 |
SHI
SV Health Investors
Boston,
Massachusetts
|
+$22.5M |
| 4 |
BlackRock
New York
|
+$15.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$37.9M |
| 2 |
Millennium Management
New York
|
-$16.1M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$5.5M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$2.34M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$2.25M |
BVS Hedge Fund Activity: Q4 2021 in Review
98 of the 6,521 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q4 2021, worth a combined $452M — up 28% from $352M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new BVS positions and 14 closed out — a net gain of 29 holders — while 41 added to existing stakes and 9 trimmed.
The largest buyer was Juniper Investment Company, adding an estimated $30.5M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $37.9M sold.
- 98 institutional investors held Bioventus (BVS) as of Q4 2021, up from 69 in Q3 2021.
- Funds reported $452M of Bioventus stock for Q4 2021, up 28% quarter-over-quarter.
- 43 funds opened new Bioventus positions in Q4 2021 and 14 closed out, a net change of +29 holders.
- The largest Bioventus buyer in Q4 2021 was Juniper Investment Company, an estimated $30.5M added.
- The largest Bioventus seller in Q4 2021 was T. Rowe Price Associates, an estimated $37.9M sold.
Based on aggregated 13F filings for Q4 2021.